Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666872 | 1.00 | KDM4E (0.42) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL3809144 | 0.94 | KDM4E (0.40) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL2157604 | 0.93 | HSD17B1 (0.39) | KDM4EMAPT | |
| SCHEMBL2157591 | 0.92 | KDM4E (0.42) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL2876741 | 0.92 | POLB (0.41) | KDM4EHTTATMMAPT | |
| SCHEMBL14521764 | 0.90 | IKBKB (0.34) | KDM4EHTTATMPTPRFPTPN1 | |
| SCHEMBL2157715 | 0.90 | PTPN1 (0.41) | KDM4EPTPN1MAPT | |
| SCHEMBL4156123 | 0.90 | PTPN1 (0.41) | KDM4EPTPN1MAPT | |
| SCHEMBL2158018 | 0.90 | IKBKB (0.44) | KDM4EPTPN1MAPT | |
| SCHEMBL14042870 | 0.90 | IKBKB (0.34) | KDM4EHTTATMPTPRFPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110958880-B | Solid dispersion preparation | 东莞东阳光太景医药研发有限责任公司 | 2023-08-08 | — | — | CN | claimed |
| EP-1401825-B1 | THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS FOR FLAVIVIRUS INFECTION | VIROCHEM PHARMA INC (CA) | 2009-08-05 | — | — | EP | claimed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | claimed |
| US-12629094-B2 | System, software and methods of using software for predicting efficacy of alzheimer's disease treatments | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250382370-A1 | ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE | GENENTECH, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4591881-A2 | ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION | F. Hoffmann-La Roche AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| EP-4331604-B9 | ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION | HOFFMANN LA ROCHE (CH) | 2025-07-23 | — | — | EP | disclosed |
| EP-3471737-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4331604-B1 | ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION | HOFFMANN LA ROCHE (CH) | 2025-03-05 | — | — | EP | disclosed |
| US-20250057837-A1 | Methods for Treating HCV | ABBVIE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2010031832-A2 | SYNERGISTIC COMBINATIONS OF A MACROCYCLIC INHIBITOR OF HCV AND A THIOPHENE-2-CARBOXYLIC ACID DERIVATIVE | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070197463-A1 | Antiviral nucleosides | PHARMASSET, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057837-A1 | Methods for Treating HCV | EIF2AK2, IFNAR1, IFNG | KDM4E 3811/4885HTT 3847/4885ATM 4740/4885 |
| US-12629094-B2 | System, software and methods of using software for predicting efficacy of alzheimer's disease treatments | MAPT, APP, PSEN2 | KDM4E 4825/4885HTT 318/4885ATM 779/4885 |
| US-20070197463-A1 | Antiviral nucleosides | RNGTT, PNP, NSUN2 | KDM4E 2574/4885HTT 4258/4885ATM 3981/4885 |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | AP1M1, AP1G1, AP3B1 | KDM4E 986/4885HTT 3689/4885ATM 2270/4885 |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | KDM4E 794/4885HTT 3552/4885ATM 4348/4885 |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | KDM4E 3168/4885HTT 2544/4885ATM 313/4885 |
| US-20080299080-A1 | Thiophene analogues for the treatment or prevention of flavivirus infections | TTR, ZC3HAV1, IRF3 | KDM4E 1474/4885HTT 1666/4885ATM 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.